乾癬の世界市場レポート 2025年

乾癬の市場規模は、今後数年間で力強い成長が見込まれます。2029年には423億4,000万米ドルに成長し、CAGRは9.4%となります。予測期間の成長は、規制当局の承認、患者の嗜好、高齢化、認知度の向上、新規治療法の導入などに起因すると考えられます。予測期間の主な動向には、研究開発の進展、生物製剤と標的療法、経口低分子療法、個別化医療、遠隔医療とデジタルヘルス、患者中心の医療、バイオシミラー、人工知能と機械学習などが含まれます。

乾癬患者の増加は、乾癬市場成長の原動力となっています。皮膚疾患である乾癬は、免疫系、遺伝、環境因子などの要因に影響されます。近年、乾癬の症例が急増しているのは、主に気候の変化、ストレスレベルの上昇、不健康なライフスタイルに起因しています。World Psoriasis Day consortiumの報告によると、世界人口の2～3％、1億2,500万人が乾癬に苦しんでいます。従って、乾癬患者の増加は、乾癬市場成長の主要な促進要因になると予想されます。

高齢者人口の増加が、今後数年間の乾癬市場拡大の原動力になると予測されています。高齢者人口は65歳以上の個人で構成されます。この層は、乾癬の症状を悪化させる高血圧、糖尿病、血糖値上昇などの疾患の有病率が著しく高い傾向があります。例えば、2022年1月、米国を拠点とする連邦政府機関である議会予算局は、社会保障の給与税と給付の対象となる人口が、2024年の3億4,200万人から2054年には3億8,300万人に増加すると予測されると報告しました。この増加の主な原因は、65歳以上の年齢層が大幅に増加し、高齢化が進むことです。その結果、高齢者人口の増加が乾癬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の乾癬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の乾癬市場：成長率分析
• 世界の乾癬市場の実績：規模と成長、2019～2024年
• 世界の乾癬市場の予測：規模と成長、2024～2029年、2034年
• 世界の乾癬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の乾癬市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• インターロイキン阻害剤
• コルチコステロイド
• 抗炎症薬
• 腫瘍壊死因子阻害剤
• 世界の乾癬市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 低分子
• 生物学的製剤
• 世界の乾癬市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 尋常性乾癬
• 爪乾癬
• 滴状乾癬
• 膿疱性乾癬
• 紅皮症乾癬
• 世界の乾癬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 局所
• 注射剤
• 世界の乾癬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 小売薬局
• eコマース
• 世界の乾癬市場：インターロイキン阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• IL-12/23阻害剤（ウステキヌマブ）
• IL-17阻害剤（セクキヌマブ、イキセキズマブ）
• 世界の乾癬市場：コルチコステロイドのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 局所コルチコステロイド（ヒドロコルチゾン、ベタメタゾン）
• 全身性コルチコステロイド（プレドニゾン）
• 世界の乾癬市場：抗炎症薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 非ステロイド性抗炎症薬（NSAID）
• 生物学的抗炎症剤（アプレミラスト）
• 世界の乾癬市場：腫瘍壊死因子（TNF）阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アダリムマブ（ヒュミラ）
• エタネルセプト（エンブレル）
• インフリキシマブ（レミケード）

第7章 地域別・国別分析

• 世界の乾癬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の乾癬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 乾癬市場：競合情勢
• 乾癬市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Johnson & Johnson
• Amgen Inc.
• Boehringer Ingelheim GmbH
• Merck & Co. Inc.
• Janssen Biotech Inc.
• Takeda Pharmaceutical Company Limited
• Stiefel Laboratories Inc.
• AstraZeneca Inc.
• Union Chimique Belge SA
• Sun Pharmaceutical Industries Ltd.
• Forward Pharma AS
• Almirall SA
• Bausch Health Companies Inc.
• Biogen Inc.
• Biocon Biopharmaceuticals Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 乾癬市場2029：新たな機会を提供する国
• 乾癬市場2029：新たな機会を提供するセグメント
• 乾癬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Psoriasis is a skin condition characterized by the development of a rash with itchy, scaly patches, typically affecting areas such as the knees, elbows, trunk, and scalp. The underlying cause is often related to an immune system dysfunction where infection-fighting cells mistakenly attack healthy skin cells.

The primary categories of drugs used to manage psoriasis include interleukin inhibitors, corticosteroids, anti-inflammatories, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates and can also be synthesized as medications. These drugs come in various forms, including small molecules and biologics, and are applied to treat different manifestations of the disease, such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. They are administered via various routes, including oral, topical, and injectable methods and can be obtained through hospitals, retail pharmacies, and e-commerce channels.

The psoriasis market research report is one of a series of new reports from The Business Research Company that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends, and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The psoriasis market size has grown rapidly in recent years. It will grow from $26.56 billion in 2024 to $29.5 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to epidemiology, patient awareness and education, healthcare infrastructure and access.

The psoriasis market size is expected to see strong growth in the next few years. It will grow to $42.34 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to regulatory approvals, patient preferences, aging population, increased awareness, introduction of novel therapies. Major trends in the forecast period include advancements in research and development, biologics and targeted therapies, oral small molecule therapies, personalized medicine, telemedicine and digital health, patient-centric care, biosimilars, artificial intelligence and machine learning.

The increasing prevalence of psoriasis patients is a driving force behind the growth of the psoriasis market. Psoriasis, a skin condition, is influenced by factors such as the immune system, genetics, and environmental factors. Over recent years, the surge in psoriasis cases can be primarily attributed to climate changes, elevated stress levels, and unhealthy lifestyles. The World Psoriasis Day consortium reports that a significant 2 to 3% of the global population, which translates to 125 million individuals, suffers from psoriasis. Consequently, the escalating number of psoriasis patients is expected to be a key driver for the growth of the psoriasis market in the foreseeable future.

The growing geriatric population is anticipated to drive the expansion of the psoriasis market in the coming years. The geriatric population comprises individuals aged 65 and older. This demographic has a significantly higher prevalence of conditions such as hypertension, diabetes mellitus, and elevated blood glucose levels, which can exacerbate psoriasis symptoms. For example, in January 2022, the Congressional Budget Office, a US-based federal agency, reported that the population eligible for Social Security payroll taxes and benefits is projected to increase from 342 million in 2024 to 383 million by 2054. This rise is primarily attributed to the substantial growth of the 65-and-older age group, contributing to an aging population. As a result, the increasing geriatric population is driving the growth of the social assistance market.

An emerging trend in the psoriasis market is the use of combination therapy. Combination therapy involves the simultaneous use of two different psoriasis treatments. Combining drugs with distinct mechanisms of action (combination therapy) often results in more significant treatment effects compared to monotherapy (using a single drug). Studies indicate that combination therapy provides more effective relief from psoriasis symptoms and is associated with fewer side effects. An example of combination therapy for treating active Psoriatic Arthritis (PsA) is the combination of Taltz (ixekizumab) with methotrexate, a development by Eli Lilly and Company.

Major companies operating in the psoriasis market are intensifying their efforts to introduce innovative products and secure approval from regulatory agencies, aiming to maximize their market revenues. The drug development and approval process is intricate and time-consuming, requiring drug sponsors to navigate the regulatory framework and marketing pathways to ensure safety and effectiveness. As an illustration, in September 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO, marking the first approved treatment for generalized pustular psoriasis (GPP) flare-ups in adults. SPEVIGO is a novel, highly selective antibody designed to inhibit the interleukin-36 receptor (IL-36R) activation, a pivotal component of an immune system signaling pathway linked to GPP development. GPP, characterized by periods of widespread eruptions of sterile pustules, is a rare and potentially life-threatening neutrophilic skin condition.

The process of approving psoriasis drugs has become more streamlined on a global scale, as evidenced by the increasing approvals of drugs for psoriasis in recent years. Some notable examples include the regulatory approval of SKYRIZI (risankizumab) for plaque psoriasis treatment in Japan and the Center for Drug Evaluation and Research's approval of Avsola (infliximab-axxq) for treating plaque psoriasis. This simplified drug approval process is expected to drive the psoriasis drugs market in the forecast period.

Major companies operating in the psoriasis market include AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Stiefel Laboratories Inc., AstraZeneca Inc., Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Forward Pharma AS, Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy's Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Dermira Inc., Galderma SA, GlaxoSmithKline PLC, Incyte Pharmaceuticals Corp., LEO Pharmacy

North America was the largest region in the psoriasis market in 2024. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psoriasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psoriasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psoriasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The psoriasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug class: Interleukin Inhibitors; Corticosteroids; Anti-Inflammatory; Tumor Necrosis Factor Inhibitor
• 2) By Drug Types: Small molecules; Biologics
• 3) By Disease Indication: Plaque Psoriasis; Nail Psoriasis; Guttate Psoriasis; Pustular Psoriasis; Erythrodermic Psoriasis
• 4) By Route Of Administration: Oral; Tropical; Injectable
• 5) By Distribution Channel: Hospitals; Retail Pharmacies; E-Commerce
• Subsegments:
• 1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab); IL-17 Inhibitors (Secukinumab, Ixekizumab)
• 2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone); Systemic Corticosteroids (Prednisone)
• 3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Biologic Anti-Inflammatory Agents (Apremilast)
• 4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade)
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Novartis AG; Eli Lilly and Company; Celgene Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Psoriasis Market Characteristics

3. Psoriasis Market Trends And Strategies

4. Psoriasis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Psoriasis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Psoriasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Psoriasis Market Growth Rate Analysis
• 5.4. Global Psoriasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Psoriasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Psoriasis Total Addressable Market (TAM)

6. Psoriasis Market Segmentation

• 6.1. Global Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interleukin Inhibitors
• Corticosteroids
• Anti-Inflammatory
• Tumor Necrosis Factor Inhibitor
• 6.2. Global Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small molecules
• Biologics
• 6.3. Global Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plaque Psoriasis
• Nail Psoriasis
• Guttate Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis
• 6.4. Global Psoriasis Market, Segmentation By Route Of Administartion, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Tropical
• Injectable
• 6.5. Global Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Retail Pharmacies
• E-Commerce
• 6.6. Global Psoriasis Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IL-12/23 Inhibitors (Ustekinumab)
• IL-17 Inhibitors (Secukinumab, Ixekizumab)
• 6.7. Global Psoriasis Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Corticosteroids (Hydrocortisone, Betamethasone)
• Systemic Corticosteroids (Prednisone)
• 6.8. Global Psoriasis Market, Sub-Segmentation Of Anti-Inflammatory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biologic Anti-Inflammatory Agents (Apremilast)
• 6.9. Global Psoriasis Market, Sub-Segmentation Of Tumor Necrosis Factor (TNF) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adalimumab (Humira)
• Etanercept (Enbrel)
• Infliximab (Remicade)

7. Psoriasis Market Regional And Country Analysis

• 7.1. Global Psoriasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Psoriasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Psoriasis Market

• 8.1. Asia-Pacific Psoriasis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Psoriasis Market

• 9.1. China Psoriasis Market Overview
• 9.2. China Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Psoriasis Market

• 10.1. India Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Psoriasis Market

• 11.1. Japan Psoriasis Market Overview
• 11.2. Japan Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Psoriasis Market

• 12.1. Australia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Psoriasis Market

• 13.1. Indonesia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Psoriasis Market

• 14.1. South Korea Psoriasis Market Overview
• 14.2. South Korea Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Psoriasis Market

• 15.1. Western Europe Psoriasis Market Overview
• 15.2. Western Europe Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Psoriasis Market

• 16.1. UK Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Psoriasis Market

• 17.1. Germany Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Psoriasis Market

• 18.1. France Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Psoriasis Market

• 19.1. Italy Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Psoriasis Market

• 20.1. Spain Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Psoriasis Market

• 21.1. Eastern Europe Psoriasis Market Overview
• 21.2. Eastern Europe Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Psoriasis Market

• 22.1. Russia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Psoriasis Market

• 23.1. North America Psoriasis Market Overview
• 23.2. North America Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Psoriasis Market

• 24.1. USA Psoriasis Market Overview
• 24.2. USA Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Psoriasis Market

• 25.1. Canada Psoriasis Market Overview
• 25.2. Canada Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Psoriasis Market

• 26.1. South America Psoriasis Market Overview
• 26.2. South America Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Psoriasis Market

• 27.1. Brazil Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Psoriasis Market

• 28.1. Middle East Psoriasis Market Overview
• 28.2. Middle East Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Psoriasis Market

• 29.1. Africa Psoriasis Market Overview
• 29.2. Africa Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Psoriasis Market Competitive Landscape And Company Profiles

• 30.1. Psoriasis Market Competitive Landscape
• 30.2. Psoriasis Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Psoriasis Market Other Major And Innovative Companies

• 31.1. Johnson & Johnson
• 31.2. Amgen Inc.
• 31.3. Boehringer Ingelheim GmbH
• 31.4. Merck & Co. Inc.
• 31.5. Janssen Biotech Inc.
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Stiefel Laboratories Inc.
• 31.8. AstraZeneca Inc.
• 31.9. Union Chimique Belge SA
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Forward Pharma AS
• 31.12. Almirall SA
• 31.13. Bausch Health Companies Inc.
• 31.14. Biogen Inc.
• 31.15. Biocon Biopharmaceuticals Pvt. Ltd.

32. Global Psoriasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Psoriasis Market

34. Recent Developments In The Psoriasis Market

35. Psoriasis Market High Potential Countries, Segments and Strategies

• 35.1 Psoriasis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Psoriasis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Psoriasis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer